TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient volunteered to participate in the study, and signed the Informed Consent~2. Age 18-75 years old, male or female~3. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL, De novo or transformed) histologically according to the 2016 WHO Classification, at least one measurable lesion(LDi≥1.5 cm)~4. r/r DLBCL patients who received prior CD19 CAR-T therapy, and positive for CD20~5. At least 2 weeks from last treatment (radiation, chemotherapy, mAb, etc) to apheresis~6. Adequate organ and bone marrow fuction~7. No contraindications of apheresis~8. Expected survival time \> 3 months~9. ECOG scores 0 - 1~Exclusion Criteria:~1. Have a history of allergy to cellular products~2. Patients with cardiac insufficiency classified as Class III or IV according to the New York Heart Association (NYHA) Heart Function Classification Standard~3. A history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease~4. Patients with active CNS involvement~5. Patients with autoimmune disease, immunodeficiency, or other treatment requiring inhibitors~6. Severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. However, prophylactic antibiotics, antiviral and antifungal treatments are allowed~7. Live vaccination within 4 weeks before peripheral blood apheresis~8. HIV, HBV, HCV and TPPA / RPR infections, and HBV carriers~9. Have a history of alcoholism, drug addiction and mental illness~10. Non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception~11. Patients with severe fludarabine or cyclophosphamide hypersensitivity~12. The patient has a history of other primary cancers, except for the following:~    1. Non-melanoma such as skin basal cell carcinoma cured by resection~   2. Cured carcinoma in situ such as cervical, bladder or breast cancer~13. The investigators believe that there are other circumstances that are not suitable for the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- C-CAR066 (Type: EXPERIMENTAL): Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Considered healthy as per medical judgment of the investigator~2. Age: 20 to 45 years~3. Sex: Male, Female and Transgender~4. For married women, a negative urine pregnancy test (Rapid Diagnostic Test) during screening and prior to first, second and third dose of vaccination.Moreover, medical history will be taken thoroughly by study physician from the woman of childbearing age to completely exclude the probability of pregnancy.The women who are married and living with a partner must agree to use a reliable contraceptive method to prevent pregnancy until final follow-up following vaccination. However abstinence is also acceptable.~Exclusion Criteria:~1. Prior history of hepatitis B infection~2. Vaccination with any hepatitis B vaccine~3. Recent febrile illness (within 2 weeks)~4. Known or suspected hypersensitivity to any component of Hepatitis B vaccine (e.g., aluminium, yeast).~5. History of received hepatitis B immune globulin (HBIG), serum immune globulin, or any other blood-derived product.~6. Known or suspected impairment of immunologic function or recent use of immunomodulatory medications (e.g., systemic corticosteroids) more than 14 days with in last 6 months. Does not include topical and inhaled steroids.~7. Receipt of investigational drugs or other investigational vaccines within 3 months prior to first injection with the study vaccine.~8. Pregnant women, nursing mothers, and women planning to become pregnant within the study period.~9. HBsAg reactive, anti-HBs antibody (≥10mlU/ml), anti-HBc (total) reactive, and abnormal liver function test \[serum alanine aminotransferase (ALT) level\], serum creatinine and CBC (As mentioned in Appendix IV).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Hepa B (Type: EXPERIMENTAL): 79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
- Engerix B (Type: ACTIVE_COMPARATOR): 79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is a healthy infant approximately 2 months of age~Exclusion Criteria:~* Birth mother is a known carrier of hepatitis B virus or another known carrier has lived in close contact with the participant~* Participant's birth mother did not receive any prenatal care~* Participant has previous history of hepatitis B infection~* Participant has been vaccinated against hepatitis B or birth mother was vaccinated within 6 months before birth of participant~* Participant has had a fever within 72 hours of study start~* Participant has received any blood-derived product or birth mother received blood-derived product within 6 months of birth of participant

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 2 Months
- Healthy Volunteers: t

Study Arms:
- Modified Process Hepatitis B vaccine 5 μg (Type: EXPERIMENTAL): Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
- RECOMBIVAX HB™ Hepatitis B Vaccine (Type: ACTIVE_COMPARATOR): Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
- Modified Process Hepatitis B vaccine 10 μg (Type: EXPERIMENTAL): Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
- ENGERIX-B® (Type: ACTIVE_COMPARATOR): Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Paravertebral Block With Dexamethasone on Intraoperative and Postoperative Analgesia in Children Undergoing Surgery for Coarctation of Aorta

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 4m-6 years males and females scheduled for surgery for coarctation of the aorta~Exclusion Criteria:~* patients with associated other cardiac anomalies (e.g. VSD), patients with airway abnormality, patients with heart failure, patients with endocrine disorders, patients with history of convulsions, neurological disorder, hepatic, renal and neuromuscular diseases, coagulopathy, history of hyperthermia, infection at site of the block and family history of hypersensitivity

- Gender: ALL
- Minimum Age: 4 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- paravertebral block with bupivacaine (Type: ACTIVE_COMPARATOR): this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
- paravertebral block with bupivacaine and dexamethasone (Type: ACTIVE_COMPARATOR): this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be at least 18 years of age;~2. Give written informed consent;~3. Be in good general health as determined by your doctor;~4. Have a diagnosis of unilateral or bilateral glaucoma or ocular hypertension;~5. If you are a female of child bearing potential, you must be willing to practice effective contraception for the duration of the study (i.e., abstinence, spermicide, condoms, or birth control pills);~6. Understand the study instructions, and be able to follow the study instructions; and~7. Be likely to complete the entire study period (12 weeks), including all regularly scheduled study visits.~Exclusion Criteria:~1. Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation;~2. Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; and~3. Concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the Screening Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
- 2 (Type: ACTIVE_COMPARATOR): Latanoprost 0.005% ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Females between 5 and 7.5 years and male between 5 and 8.5 years of age with normal heights, a history of mild persistent asthma for at least 3 months prior to visit 1, a forced expiratory volume in one second (FEV1) of ³80% of predicted following at least a 4-hour albuterol withhold, and treated with non-corticosteroid asthma medications on an as-needed or daily basis, or with low doses of inhaled corticosteroids (ICSs) for at least one month prior to Visit 1. Subjects were to be no greater than Stage 1 in the Tanner classification of sexual maturity, and they had to be able to demonstrate effective use of the MDI devices and perform reproducible pulmonary function test.~Exclusion Criteria:~* Subjects with a history of life-threatening asthma, severe respiratory impairment, history of abnormal growth, concurrent disease or condition which may substantially affect growth, previous requirement for daily or alternate day oral corticosteroids (OCS) treatment for ³60 days within the 2 years of Visit 3 and/or any use of OCS within 30 days prior to Visit 1 or during the run-in period, previous treatment with moderate or high doses of inhaled corticosteroid during the 30 days prior to Visit 1

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 102 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects aged from 5 to 22 years old as established by medical history and clinical examination~* The subjects or their guardians are able to understand and sign the informed consent~* Had never received the vaccine against EV71~* Subjects who can and will comply with the requirements of the protocol~Exclusion Criteria:~* Subject that has a medical history of HFMD~* subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine~* Family history of seizures or progressive neurological disease~* Family history of congenital or hereditary immunodeficiency~* Women of pregnancy, lactation or about to be pregnant in 60 days~* Autoimmune disease or immunodeficiency~* Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws~* Any prior administration of administration of immunoglobulins

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- 320U /0.5ml in young adults (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 young adults aged 16-22 years old on day0,28
- 640U /0.5ml in young adults (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 young adults aged 16-22 years old on day0,28
- 160U /0.5ml in children (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 20 children aged 5-15 years old on day0,28
- 320U /0.5ml in children (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 children aged 6-15 years old on day0,28
- 640U /0.5ml in children (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 children aged 6-15 years old on day0,28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mini-CHOP and Rituximab in Patients Aged Over 80 Years

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification). DLBCL with some small cell infiltration in bone marrow or lymph node may be included.~* Aged over 80 years.~* Ann Arbor stage I bulky, II, III or IV~* Age-adjusted International Prognostic Index equal to 0, 1, 2 and 3.~* Patient non previously treated.~* ECOG performance status ≤ 2.~* With a minimum life expectancy of 3 months.~* Negative HIV, HBV and HCV serologies test ≤ 4 weeks (except after vaccination).~* Having previously signed a written informed consent~Exclusion Criteria:~* Any other histological type of lymphoma.~* Any history of treated or non-treated indolent lymphoma.~* Central nervous system or meningeal involvement by lymphoma.~* Contra-indication to any drug contained in the chemotherapy regimens.~* Any serious active disease (according to the investigator's decision).~* Poor renal function (creatinin level\>150µmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration.~* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~* Adult patient under tutelage.

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R mini CHOP (Type: EXPERIMENTAL): Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criterion applicable to All Groups~* Subjects aged 2 to 17 years (inclusive) at enrollment~* weighing at least 13 Kg at the time of enrollment~Inclusion criterion applicable to Group A - Subjects at risk of meningococcal disease because of primary or secondary complement deficiencies~Inclusion criterion applicable to Group B~- Subjects at risk of meningococcal disease because of functional or anatomic asplenia~Inclusion criterion applicable to Group C - healthy subjects~Exclusion Criteria:~Exclusion criteria applicable to All Groups (A, B and C)~* History of any previous immunization with a meningococcal B vaccine~* History of severe allergic reaction after previous vaccinations, or hypersensitivity to any component of the vaccine~* Known HIV infection~* History of any progressive or severe neurologic disorder or seizure disorder~* Contraindication to intramuscular injection or blood drawn~* Females who are pregnant, planning a pregnancy or nursing (breastfeeding)~* Females of childbearing potential who have not used or do not plan to use acceptable birth control measures~* History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects~Exclusion criterion applicable to Groups A and B~- Previous known or suspected disease caused by N. meningitidis in the last year.~Exclusion criteria applicable to Group C~* Previous known or suspected disease caused by N. meningitidis~* Known or suspected impairment/alteration of the immune system

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Complement deficiency
- Group B (Type: EXPERIMENTAL): asplenia/splenic dysfunction
- Group C (Type: ACTIVE_COMPARATOR): age-matched healthy controls

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes mellitus according to the ADA criteria~* HbA1c between 6.5% and 8.5%~* Individually optimized combination therapy with metformin in combination with sulfonylurea in a stable dosage within the last 3 months~* Age between 40 and 75 years~* Fasting intact proinsulin level \> 7 pmol/Land \< 20 pmol/Lat screening~Exclusion Criteria:~* Type 1 Diabetes mellitus~* Pre-Treatment with insulin within the last 3 months prior to screening~* Pre-Treatment with PPARy-agonists (glitazones) within the last 3 months prior to screening~* Major micro- or macrovascular complications as judged by the investigator~* BMI \> 40 kg/m²~* Hypokalemia (K \< 3.5 mmol /L)~* History of drug or alcohol abuse~* Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures~* History of severe or multiple allergies~* Treatment with any other investigational drug within 3 months prior to screening~* Progressive fatal disease~* History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT \> 3 times the normal reference range), renal (creatinine \> 1.3 mg/dL in women and \> 1.7 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator~* Pregnancy or breast feeding~* Sexually active women of childbearing potential not actively and consistently practicing birth control by using a medically accepted device or therapy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)
- NPH Insulin (Type: ACTIVE_COMPARATOR): NPH Insulin, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)
- Insulin detemir (Type: ACTIVE_COMPARATOR): Insulin detemir, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete